Mirati Therapeutics (MRTX) stock Forecast for 2022 – 2026
Last update: 05-20-2022, 7:09
Sector: HealthcareThe share price of Mirati Therapeutics, Inc. (MRTX) now
What analysts predict:: $148.64
52-week high/low: $195.99 / $51.16
50/200 Day Moving Average: $75.55 / $127.29
This figure corresponds to the average price over the previous 50/200 days. For Mirati Therapeutics stocks, the 50-day moving average is the resistance level today.
For Mirati Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Mirati Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Mirati Therapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one Mirati Therapeutics share be worth in 2022 - 2026?
When should I take profit in Mirati Therapeutics stock? When should I record a loss on Mirati Therapeutics stock? What are analysts' forecasts for Mirati Therapeutics stock? What is the future of Mirati Therapeutics stock?
We forecast Mirati Therapeutics stock performance using neural networks based on historical data on Mirati Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Mirati Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Mirati Therapeutics shares. This happens once a day.
Historical and forecast chart of Mirati Therapeutics stock
The chart below shows the historical price of Mirati Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Mirati Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
Mirati Therapeutics daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May 22 | 61.10 | 60.40 | 61.79 | 2.30 |
| May 23 | 60.89 | 59.63 | 62.23 | 4.36 |
| May 24 | 58.99 | 57.98 | 60.23 | 3.88 |
| May 25 | 59.36 | 58.57 | 60.51 | 3.30 |
| May 26 | 58.82 | 57.57 | 59.79 | 3.86 |
| May 27 | 60.24 | 58.77 | 61.59 | 4.81 |
| May 28 | 59.44 | 58.53 | 60.34 | 3.09 |
| May 29 | 59.01 | 57.83 | 60.51 | 4.64 |
| May 30 | 60.39 | 58.70 | 61.15 | 4.18 |
| May 31 | 59.40 | 58.50 | 60.56 | 3.52 |
| Jun 01 | 57.84 | 57.23 | 58.49 | 2.19 |
| Jun 02 | 58.93 | 58.00 | 60.04 | 3.52 |
| Jun 03 | 59.34 | 58.14 | 60.44 | 3.97 |
| Jun 04 | 59.03 | 58.56 | 60.35 | 3.07 |
| Jun 05 | 60.13 | 59.47 | 61.64 | 3.64 |
| Jun 06 | 60.34 | 59.45 | 60.82 | 2.31 |
| Jun 07 | 61.63 | 60.46 | 62.79 | 3.85 |
| Jun 08 | 60.76 | 60.34 | 62.40 | 3.42 |
| Jun 09 | 61.44 | 60.09 | 62.37 | 3.79 |
| Jun 10 | 60.11 | 59.50 | 61.77 | 3.82 |
| Jun 11 | 60.43 | 60.00 | 61.57 | 2.61 |
| Jun 12 | 58.75 | 58.04 | 59.37 | 2.30 |
| Jun 13 | 60.05 | 59.44 | 60.64 | 2.02 |
| Jun 14 | 61.65 | 60.74 | 62.99 | 3.69 |
| Jun 15 | 63.31 | 62.80 | 64.33 | 2.43 |
| Jun 16 | 64.31 | 63.23 | 65.45 | 3.52 |
| Jun 17 | 63.00 | 62.03 | 63.86 | 2.95 |
| Jun 18 | 62.27 | 61.49 | 63.56 | 3.37 |
| Jun 19 | 62.25 | 61.60 | 63.65 | 3.32 |
| Jun 20 | 60.66 | 60.11 | 61.53 | 2.37 |
Mirati Therapeutics Daily Price Targets
Mirati Therapeutics Stock Forecast 05-22-2022.
Pessimistic target level: 60.40
Optimistic target level: 61.79
Mirati Therapeutics Stock Forecast 05-23-2022.
Pessimistic target level: 59.63
Optimistic target level: 62.23
Mirati Therapeutics Stock Forecast 05-24-2022.
Pessimistic target level: 57.98
Optimistic target level: 60.23
Mirati Therapeutics Stock Forecast 05-25-2022.
Pessimistic target level: 58.57
Optimistic target level: 60.51
Mirati Therapeutics Stock Forecast 05-26-2022.
Pessimistic target level: 57.57
Optimistic target level: 59.79
Mirati Therapeutics Stock Forecast 05-27-2022.
Pessimistic target level: 58.77
Optimistic target level: 61.59
MRTX (MRTX) Monthly Stock Prediction for 2022
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jun. | 55.79 | 52.70 | 61.06 | 13.70 |
| Jul. | 57.97 | 52.58 | 63.01 | 16.56 |
| Aug. | 60.32 | 54.71 | 63.21 | 13.45 |
| Sep. | 51.99 | 47.39 | 55.89 | 15.21 |
| Oct. | 48.09 | 43.04 | 52.64 | 18.23 |
| Nov. | 49.90 | 43.98 | 52.52 | 16.25 |
| Dec. | 48.92 | 46.80 | 50.61 | 7.54 |
Mirati Therapeutics forecast for this year
Mirati Therapeutics Stock Prediction for Jun 2022
An downtrend is forecast for this month with an optimal target price of $55.7924. Pessimistic: $52.70. Optimistic: $61.06
Mirati Therapeutics Stock Prediction for Jul 2022
An uptrend is forecast for this month with an optimal target price of $57.9683. Pessimistic: $52.58. Optimistic: $63.01
Mirati Therapeutics Stock Prediction for Aug 2022
An uptrend is forecast for this month with an optimal target price of $60.316. Pessimistic: $54.71. Optimistic: $63.21
Mirati Therapeutics Stock Prediction for Sep 2022
An downtrend is forecast for this month with an optimal target price of $51.9924. Pessimistic: $47.39. Optimistic: $55.89
Mirati Therapeutics Stock Prediction for Oct 2022
An downtrend is forecast for this month with an optimal target price of $48.0929. Pessimistic: $43.04. Optimistic: $52.64
Mirati Therapeutics Stock Prediction for Nov 2022
An uptrend is forecast for this month with an optimal target price of $49.8964. Pessimistic: $43.98. Optimistic: $52.52
Mirati Therapeutics Stock Prediction for Dec 2022
An downtrend is forecast for this month with an optimal target price of $48.9235. Pessimistic: $46.80. Optimistic: $50.61
Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 45.69 | 43.30 | 49.12 | 11.86 |
| Feb | 48.30 | 42.50 | 49.75 | 14.56 |
| Mar | 46.71 | 41.24 | 48.18 | 14.40 |
| Apr | 43.20 | 40.61 | 47.41 | 14.35 |
| May | 44.04 | 41.07 | 46.89 | 12.40 |
| Jun | 47.08 | 45.39 | 50.40 | 9.95 |
| Jul | 51.11 | 47.97 | 55.63 | 13.78 |
| Aug | 55.02 | 48.75 | 60.71 | 19.71 |
| Sep | 51.88 | 46.75 | 53.52 | 12.65 |
| Oct | 58.89 | 56.06 | 65.42 | 14.31 |
| Nov | 64.98 | 57.96 | 69.17 | 16.20 |
| Dec | 74.53 | 71.40 | 79.79 | 10.51 |
Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 73.19 | 69.68 | 78.35 | 11.07 |
| Feb | 77.26 | 70.77 | 84.56 | 16.31 |
| Mar | 79.92 | 73.81 | 85.68 | 13.85 |
| Apr | 71.65 | 64.66 | 77.45 | 16.51 |
| May | 72.51 | 69.68 | 79.36 | 12.20 |
| Jun | 68.38 | 64.68 | 76.58 | 15.54 |
| Jul | 66.84 | 59.12 | 74.76 | 20.92 |
| Aug | 70.55 | 65.15 | 73.62 | 11.50 |
| Sep | 72.13 | 67.91 | 76.35 | 11.05 |
| Oct | 62.40 | 58.37 | 67.26 | 13.22 |
| Nov | 65.02 | 59.85 | 71.94 | 16.81 |
| Dec | 67.45 | 59.46 | 71.91 | 17.31 |
Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 76.76 | 68.36 | 85.28 | 19.85 |
| Feb | 77.80 | 68.58 | 80.60 | 14.91 |
| Mar | 82.47 | 77.15 | 84.94 | 9.17 |
| Apr | 87.66 | 84.38 | 97.53 | 13.48 |
| May | 84.77 | 78.29 | 87.31 | 10.34 |
| Jun | 78.41 | 75.00 | 83.82 | 10.52 |
| Jul | 78.29 | 74.42 | 86.87 | 14.33 |
| Aug | 77.36 | 70.51 | 82.93 | 14.97 |
| Sep | 73.99 | 69.22 | 77.65 | 10.86 |
| Oct | 69.44 | 66.42 | 75.27 | 11.76 |
| Nov | 67.88 | 65.43 | 72.66 | 9.95 |
| Dec | 69.40 | 65.14 | 72.01 | 9.54 |
Mirati Therapeutics (MRTX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 74.71 | 72.02 | 80.54 | 10.58 |
| Feb | 78.08 | 74.68 | 86.39 | 13.56 |
| Mar | 80.18 | 71.52 | 89.21 | 19.82 |
| Apr | 83.55 | 77.41 | 86.94 | 10.96 |
| May | 80.54 | 76.44 | 90.09 | 15.15 |
| Jun | 78.97 | 72.34 | 86.67 | 16.54 |
| Jul | 83.71 | 78.06 | 91.62 | 14.80 |
| Aug | 89.49 | 79.29 | 92.71 | 14.48 |
| Sep | 87.74 | 83.01 | 97.22 | 14.62 |
| Oct | 83.40 | 77.15 | 87.03 | 11.36 |
| Nov | 72.02 | 66.72 | 74.50 | 10.44 |
| Dec | 61.97 | 55.65 | 67.92 | 18.07 |
Mirati Therapeutics information and performance
Mirati Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is focused on developing a pipeline of targeted cancer drugs. The company is developing candidate products to combat genetic and immunological cancer promoters. Its clinical programs consist of two candidate products: MRTX849, a Kirsten rat sarcoma inhibitor (KRAS) G12C, and Sitravatinib, a multi-kinase inhibitor. His KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit the KRAS G12C mutations that are present in patients with non-small cell lung cancer (NSCLC), adenocarcinoma, colorectal cancer (CRC), pancreatic cancer, and several other intractable cancers. Sitravatinib is a spectrally selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs) including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
Mirati Therapeutics Address
9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA, US
Market Capitalization: 3 156 149 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -148 816 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: -11.21
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.825
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 25.76
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 55527000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A